GLP1 reverses diabetes in human cells (in mice)
Scientists managed to increase the number of insulin-producing cells in a human-cell-in-mouse experiment.
Latest
category:side-effects
Thyroid issues with GLP1?
Do GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) cause thyroid issues?
includes:study
Are GLP1 side effects all the same?
Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.
category:news
23andMe gets into GLP1
23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.
includes:review
Systematic reviews of GLP1 worth reading
Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.
drug:amycretin
Novo's new GLP1: Amycretin
Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.
category:news
GLP1's effect on ADHD
What effects does GLP1 have on ADHD? It's early, but we take a look at some published research.
categeory:watercooler
Life before GLP1s: Topiramate
Wondering what the world was doing before GLP1s? We discuss Topiramate, a popular appetite suppressant.
category:news
A new GLP1: Retatrutide
Is mimicking more hormones better? Let's find out -- the new GLP1 drug Retatrutide is a *triple* receptor agonist
category:news
Are GLP1s primarily brain drugs?
Are GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, etc) primarily brain drugs?
company:eli-lilly
Eli Lilly China approval and new suppliers
As the race to manufacture more GLP1 medications intensifies, Eli Lilly gets approval in China and more suppliers.
chemical:semaglutide
24% Less kidney disease risk with Semaglutide (Ozempic)
Can we trust research funded by Novo Nordisk which found a 24% decrease in kidney disease risk for people on Semaglutide (Ozempic)?